Shireen Fatemi, MD, FACE, FACP

Biography

Associate Professor

Clinical Science

Dr. Shireen Fatemi is a Southern California Permanente Medical Group physician serving as Physician-in-Charge in the Department of Internal Medicine at Kaiser Permanente Panorama City Medical Center. With a research emphasis on thyroid cancer, Dr. Fatemi has published and presented on this topic widely.

Education and Training

Degrees: BS, with honors, Immaculate Heart College Los Angeles
MD, University of Health Sciences, The Chicago Medical School

Internship: Intern, Internal Medicine, University of California Los Angeles Wadsworth Veterans’ Administration, Medical Center, West Los Angeles

Residency: Resident, Internal Medicine, University of California Los Angeles Wadsworth Veterans’ Administration, Medical Center, West Los Angeles

Fellowship: Postdoctoral Fellow, Endocrinology, Diabetes, And Metabolism, University of Southern California School of Medicine

Professional Positions

Chief, Division of Endocrinology: Kaiser Permanente Panorama City Medical Center; 1997-present

Clinical Professor of Medicine, Voluntary Faculty: Keck School of Medicine of USC; 2002-present

Regional Co-Lead, Healthy Bones Program: Southern California Permanente Medical Group; 2002-present

Assistant Area Medical Director: Kaiser Permanente Panorama City Medical Center; 2007-present

Clinical Lead: National Kaiser Permanente Osteoporosis and Fracture Prevention Clinical Guidelines Committee; 2017-present

Honors and Awards

Exceptional Physician Contribution Award: Kaiser Permanente Panorama City Medical Center; 2006

Regional Co-Lead, Healthy Bones Model of Care, Voh’s Award Winner for Quality: Southern California Permanente Medical Group; 2009

The Endocrine Society Journal Awards for best clinical research paper: Journal of Clinical Endocrinology and Metabolism; 2012

ASBMR Most Outstanding Clinical Abstract Award: The American Society for Bone and Mineral Research; 2017

Internist of the Year: Southern California Permanente Medical Group, Kaiser Permanente Panorama City Medical Center; 2017

Scholarly Activities

Peer-reviewed research manuscripts

Spencer CA, Petrovic I, Fatemi S. Current Thyroglobulin Autoantibody (TgAb) Assays Often Fail to Detect Interfering TgAb that Can Result in the Reporting of Falsely Low/Undetectable Serum Tg IMA Values for Patients with Differentiated Thyroid Cancer. J Clin Endocrinol & Metab. 2011; 96: 1283-1291.
Spencer C, Fatemi S. Thyroglobubin Autoantibody (TgAB) Methods–strengths, pitfalls, and clinical utility for monitoring TgAB positive patients with differentiated thyroid cancer. September 2013. Best Practice and Research Clinical Endocrinology and Metabolism 27 (2013) 701-712.
Spencer C, LoPresti H, Fatemi S. How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies. Curr Opin Endocrinol Diabetes Obes 2014, 21:394-404.
Spencer C, Petrovic I, Fatemi S, LoPresti J. Serum Thyroglobulin (Tg) Monitoring of Patients with Differentiated Thyroid Cancer (DTC) using Sensitive (Second-Generation) Immunometric Assays (Tg2GIMA) can be Disrupted by False-Negative and False-Positive Serum Thyroglobulin Autoantibody (TgAb) Misclassifications. J Clin Endocrinol Metab 2014 Dec; 99(12):4589-99.
Adams A, Fischer H, Kopperdahl D, Lee D, Black D, Bouxsein M, Fatemi S, Khosla S, Orwoll E, Siris E, Keveny T. Osteoporosis and Hip Fracture Risk from Routine Computed Tomography Scans: The Fracture, Osteoporosis, and CT Utilization Study (FOCUS). Journal of Bone and Mineral Research. Vol. 33, Issue 7, July 2018, pp. 1291-1301.